Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lamivudine

FDA-approved product (tablet, oral), marketed as Epivir, Epivir-Hbv, Lamivudine.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Lamivudine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Inflammation
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF05; FDA class Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Lamivudine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli9.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lamivudine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lamivudine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients

    NCT00872417 · start 2009-03

    Registered record
    Registry ID
    NCT00872417
    Conditions
    Acquired Immune Deficiency Syndrome; HIV Infections
    Interventions
    first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT); second line ARV therapy (3TC+TDF+LPV/RTV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-03
    Completion
    2010-12
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immune Deficiency Syndrome; HIV Infections
    Interventionfirst line ARV (3TC+NVP+D4T or 3TC+NVP+AZT); second line ARV therapy (3TC+TDF+LPV/RTV)
    PhasePhase 4
    Registry statusUnknown

  • Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus

    NCT01788371 · start 2009-03

    Registered record
    Registry ID
    NCT01788371
    Conditions
    Hepatitis B Infection; Chronic Infection; Viremia
    Interventions
    Telbivudine; Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03
    Completion
    2013-07
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B Infection; Chronic Infection; Viremia
    InterventionTelbivudine; Lamivudine
    PhasePhase 4
    Registry statusCompleted

  • Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients

    NCT00558493 · start 2007-11

    Registered record
    Registry ID
    NCT00558493
    Conditions
    Chronic Hepatitis B
    Interventions
    Clevudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-11
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionClevudine
    PhasePhase 4
    Registry statusCompleted

  • KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects

    NCT00549198 · start 2007-06

    Registered record
    Registry ID
    NCT00549198
    Conditions
    Infection, Human Immunodeficiency Virus I; HIV Infection
    Interventions
    Abacavir/lamivudine and efavirenz; Tenofovir/Emtricitabine and efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-06
    Completion
    2009-12
    Enrolment
    392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus I; HIV Infection
    InterventionAbacavir/lamivudine and efavirenz; Tenofovir/Emtricitabine and efavirenz
    PhasePhase 4
    Registry statusCompleted

  • A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection

    NCT00393484 · start 2007-02

    Registered record
    Registry ID
    NCT00393484
    Conditions
    Chronic Hepatitis B
    Interventions
    Entecavir; Lamivudine Placebo; Lamivudine; Entecavir Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-02
    Completion
    2013-09
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionEntecavir; Lamivudine Placebo; Lamivudine; Entecavir Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Long Term, Safety Study of Apricitabine in HIV-infected Subjects

    NCT00367952 · start 2006-08

    Registered record
    Registry ID
    NCT00367952
    Conditions
    HIV Infection
    Interventions
    apricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2010-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    Interventionapricitabine
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment

    NCT00332306 · start 2006-06

    Registered record
    Registry ID
    NCT00332306
    Conditions
    Tuberculosis; Human Immunodeficiency Virus Infections
    Interventions
    Didanosine, Lamivudine, Efavirenz; Didanosine, Lamivudine, Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-06
    Completion
    2011-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus Infections
    InterventionDidanosine, Lamivudine, Efavirenz; Didanosine, Lamivudine, Nevirapine
    PhasePhase 3
    Registry statusUnknown

  • A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

    NCT00110305 · start 2005-06

    Registered record
    Registry ID
    NCT00110305
    Conditions
    Human Immunodeficiency Virus Type 1
    Interventions
    TMC278 25 mg; TMC278 75 mg; TMC278 150 mg; Efavirenz; Non-nucleoside reverse transcriptase inhibitor (NRTIs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-06
    Completion
    2011-12
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Type 1
    InterventionTMC278 25 mg; TMC278 75 mg; TMC278 150 mg; Efavirenz +1 more
    PhasePhase 2
    Registry statusCompleted

  • Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

    NCT00098293 · start 2004-11

    Registered record
    Registry ID
    NCT00098293
    Conditions
    HIV-1
    Interventions
    Maraviroc + Zidovudine/Lamivudine; Efavirenz + Zidovudine/Lamivudine; Maraviroc (UK-427,857) + Zidovudine/Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-11
    Completion
    2012-12
    Enrolment
    916

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionMaraviroc + Zidovudine/Lamivudine; Efavirenz + Zidovudine/Lamivudine; Maraviroc (UK-427,857) + Zidovudine/Lamivudine
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

    NCT00095121 · start 2004-06

    Registered record
    Registry ID
    NCT00095121
    Conditions
    Chronic Hepatitis B
    Interventions
    Placebo (PLB); Adefovir Dipivoxil (ADV); Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-06
    Completion
    2010-04
    Enrolment
    173

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionPlacebo (PLB); Adefovir Dipivoxil (ADV); Lamivudine
    PhasePhase 3
    Registry statusCompleted

  • Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression

    NCT00336778 · start 2004-01

    Registered record
    Registry ID
    NCT00336778
    Conditions
    HIV Infections
    Interventions
    3TC, TDF, NLV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-01
    Completion
    2008-04
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Intervention3TC, TDF, NLV
    PhasePhase 1
    Registry statusCompleted

  • Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV

    NCT00144157 · start 2003-06

    Registered record
    Registry ID
    NCT00144157
    Conditions
    Acquired Immunodeficiency Syndrome
    Interventions
    Nevirapine; Zidovudine; 3TC
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-06
    Completion
    2006-07
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome
    InterventionNevirapine; Zidovudine; 3TC
    PhasePhase 4
    Registry statusCompleted

  • A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

    NCT00650637 · start 2003-01

    Registered record
    Registry ID
    NCT00650637
    Conditions
    Diarrhea
    Interventions
    Calcium Carbonate; nelfinavir; lamivudine; loperamide; Calcium carbonate not administered; nelfinavir; lamivudine + zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2003-01
    Completion
    2003-08
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiarrhea
    InterventionCalcium Carbonate; nelfinavir; lamivudine; loperamide +3 more
    PhasePhase 3
    Registry statusTerminated

  • Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

    NCT00158405 · start 2002-12

    Registered record
    Registry ID
    NCT00158405
    Conditions
    HIV Infections
    Interventions
    Structured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV); Ritonavir (NRV); Indinavir (IDV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-12
    Completion
    2006-12
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionStructured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV) +2 more
    PhasePhase 3
    Registry statusCompleted

  • Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

    NCT00013702 · start 2001-03

    Registered record
    Registry ID
    NCT00013702
    Conditions
    Hepatitis B; HIV Infection
    Interventions
    Adefovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-03
    Completion
    2004-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; HIV Infection
    InterventionAdefovir
    PhasePhase 2
    Registry statusCompleted